All News
Figueroa Parra @AliDuarteMD et al. Multimorbidity in SLE. Higher at classification - due to non-SLE assoc. SLE-assoc drive increased accumulation over time but non-SLE assoc also increased @RheumNow #ACR22 Abstr#2091 https://t.co/6IyhovSNYA https://t.co/qmYfoqCTtz
Richard Conway RichardPAConway ( View Tweet)
Kavanaugh et al. TYK2i deucravacitinib in PsA. Nice breakdown of MDA and its components over 16 weeks. MDA achieved 23-24% with deucravacitinib at 16 weeks vs 8% with placebo @RheumNow #ACR22 Abstr#2136 https://t.co/9IG8CeZzMh https://t.co/Vg8E20y7Z8
Richard Conway RichardPAConway ( View Tweet)
Rhee @RennieRhee et al. Combined cranial vessel wall and orbital MRI for GCA. Improves sensitivity 77% vs 69% with loss of specificity 91% vs 95%. Identifies abnormalities in some without visual symptoms - at risk of vision loss @RheumNow #ACR22 Abstr#1618 https://t.co/OtGm7sEWtU https://t.co/YM4WLahubH
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr#2055 SRI-4 and BICLA: how do they converge and diverge? Analyses of 6 x Non-Renal #Lupus RCT showed discordance (12-30%).When discordant, SRI-4 classified more pts as responders vs BICLA. Concordance higher at 52 vs 24 wks. Vital to interpret both outcomes @RheumNow https://t.co/prSfTrv0E8
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Charlton et al PsA patients face longer diagnostic delay and less intensive treatment than RA patients for equivalent disease activity. @RheumNow #ACR22 Abstr#1613 https://t.co/HedK59QsKs https://t.co/xaJUy7w1t4
Richard Conway RichardPAConway ( View Tweet)
Karmacharya @rheum_cat et al. Comorbidity clusters in AS. Depression cluster associated higher disease activity and worse function over time. @RheumNow #ACR22 Abstr#1609 https://t.co/lFVoyhy5UQ https://t.co/26EjzXULGr
Richard Conway RichardPAConway ( View Tweet)
The pandemic has brought many challenges to our community. One of them is the lingering effects of COVID-19.
#PASC #COVID #ACR22 #RheumTwitter
https://t.co/AlwUHX2cao
Akhil Sood MD AkhilSoodMD ( View Tweet)
Spinal lesions on MRI in axSpA is ~3% in patients with negative imaging in SIJ on MRI or X-ray. Agreement in >5/9 central readers. Frequency of spinal vertebral corner BME lesions was significantly higher these cases. Maksymovych Abs#2257 https://t.co/56yxGxBgLp #ACR22 @RheumNow https://t.co/CkJ9o2dJuT
Dr. Antoni Chan synovialjoints ( View Tweet)
Mease et al. TYK2i Deucravacitinib in PsA. Phase 2 RCT 52 week results. PASDAS, DAPSA efficacy maintained through week 52. No new safety concerns. @RheumNow #ACR22 Abstr#1598 https://t.co/sRKkgkYtQJ https://t.co/YMXMEH3wsq
Richard Conway RichardPAConway ( View Tweet)
Ogdie @AlexisOgdie et al. CorEvitas, PsA treatment after 1st line TNFi failure. Switching MOA probably more effective @RheumNow #ACR22 Abstr#1600 https://t.co/vy8gxDaYxZ https://t.co/NmkESbSNfL
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr#1764 In addition to race, what social health aspect to consider when assessing #lupus epidemiology? A study identified urbanicity and area deprivation index were associated with SLE diagnosis. Could those living in the city = better access and diagnosis? @RheumNow https://t.co/PsNt8vQufs
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#2033 How negative is sero-ve #Sjogren? A study discovered new autoantibodies using Peptidome Array Technology. AUC for these 8 peptides was excellent 0.97. Mainly in White/Hispanic. Need validation in other groups and association with other markers/biopsy @RheumNow https://t.co/xAFrjK9mS3
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Urine Proteomics in SLE with Dr. Michelle Petri
Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at #ACR22.
https://t.co/rBDnbSqQCI https://t.co/WfERf1k5VB
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Year in Review | Presented by Dr. Carol Langford at #ACR22
🌟 Review the Most Important Clinical Research Studies in the Past Year in #Rheumatology! 💫 https://t.co/Ao11xX1bYt
Mithu Maheswaranathan, MD MithuRheum ( View Tweet)
Preventing #rheumatoid #arthritis - the holy grail! STOPRA RCT of strong ACPA+; CCP3 high titre. No inflammatory arthritis. RCT of #Hydroxychloroquine vs placebo, N=142 Pts. At 3 yrs NO DIFF in onset@of RA in each group. identical curves. Abst1604 #ACR22 #ACRBest @RheumNow Darn! https://t.co/bEgbkxGSR4
Janet Pope Janetbirdope ( View Tweet)
#ACRBest Abstracts - Day 2
Day two at #ACR22 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for today.
https://t.co/lAG1v2dHKQ https://t.co/oAG6zE7QzX
Links:
Dr. John Cush RheumNow ( View Tweet)
Pike M Abstract 1113. Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study #ACRBest #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Most VEXAS pts have pulm involvement on HRCT. Pulmonary manifestations of VEXAS are nonspecific and characterized predominantly by inflammatory parenchymal involvement. Abs 1569 #ACR22 @RheumNow https://t.co/7AB3b9e7Lt https://t.co/ikhQMEu5GA
Dr. Rachel Tate uptoTate ( View Tweet)
Sarilumab demonstrated efficacy in difficult to treat GC resistant PMR patients. Abs 1543 #ACR22 @RheumNow https://t.co/TCo5g5i1qh https://t.co/tZOhvvuhpY
Dr. Rachel Tate uptoTate ( View Tweet)
Does lifestyle impact Tx. response?
#Abstr 1510 looked at effect of lifestyle on TNFi response in #axSpA
- The study found higher BMI (obese, overweight) and smoking were less likely to respond to TNFi
- Important to discuss lifestyle when starting tx.
@RheumNow #ACR22 https://t.co/z98DFMLxu3
Akhil Sood MD AkhilSoodMD ( View Tweet)